| ||Audit Committee||Compensation Committee||Nominating and Corporate Governance Committee|
|Rich Aldrich |
Co-Founder and Chairman
Mr. Aldrich is a Co-Founder of OvaScience and is Chairman of the company’s Board of Directors. Mr. Aldrich is also a Founder and Partner of Longwood Fund, which founds and invests in biotechnology companies. Mr. Aldrich has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008), Concert Pharmaceuticals, Alnara Pharmaceuticals (acquired by Eli Lilly in 2010) and Verastem (NASDAQ: VSTM). Prior to co-f...
| || ||
|Jeffrey D. Capello
|Jeffrey D. Capello|
Jeffrey D. Capello is the Executive Vice President and Chief Financial Officer of Boston Scientific (NYSE: BSX), a position he has held since March 2010. He is directly responsible for the worldwide management of Boston Scientific's Finance Information Systems, Business Development and Corporate Strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific, he was the ...
|| || |
|Mary Fisher |
Ms. Fisher brings more than 25 years of experience in the pharmaceutical and biotechnology industries. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience, a former division of SkinMedica, Inc., where she served as Chief Executive Officer from 2008 until 2012, when she led the successful sale of the company to Allergan, Inc. for $375 million. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, where she was responsible ...
|John Howe, M.D. |
|John Howe, M.D.|
Dr. Howe is a recognized expert in international medicine and is a humanitarian leader. From 2001 through 2015, he served as the President and Chief Executive Officer of Project HOPE, an international health education and humanitarian assistance foundation, which operates more than 70 programs in 45 countries on five continents. During Dr. Howe’s tenure, Project HOPE expanded its areas of distributing medicine, treating infectious diseases and non-communicable diseases, and promoting the he...
|Marc Kozin |
Mr. Kozin has nearly 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management, both domestically and internationally. Mr. Kozin served as president of the North American practice of L.E.K., a global strategy consulting firm, for 15 years and has been a Senior Advisor to L.E.K. since July 2011. He currently serves as a member of the Board of Directors of UFP Technologies, Inc., DYAX Corp., Endocyte, Inc., and three p...
| || ||
|Thomas Malley |
Thomas Malley has served on our board of directors since October 2012. He has been President of Mossrock Capital, a private investment firm in Denver, Colorado, since 2007. From 1991 until 2007 Mr. Malley worked at Janus Mutual Funds. From 1999–2007, he started and served as the portfolio manager of the Janus Global Life Sciences Fund, as well as being Vice President in charge of the Janus Healthcare team. From 1991-1998 he served as an equity analyst for Janus covering healthcare and b...